Ratings by Credit Suisse (Tiago Fauth)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 5/23/2023 | VectivBio Holding AG | VECT | Downgrade | Neutral (Outperform) |
11.90 (16.85) |
41.6% | Details | |
| 5/5/2023 | AbCellera Biologics | ABCL | Maintain | Outperform (N/A) |
|
Details | ||
| 5/5/2023 | Apellis Pharmaceuticals | APLS | Maintain | Neutral (N/A) |
|
Details | ||
| 4/28/2023 | Ascendis Pharma | ASND | Maintain | Neutral (N/A) |
|
Details | ||
| 4/27/2023 | BioMarin Pharmaceutical Inc. | BMRN | Maintain | Outperform (N/A) |
|
Details | ||
| 4/5/2023 | Inflarx NV | IFRX | Maintain | Underperform (N/A) |
|
Details | ||
| 4/3/2023 | Ascendis Pharma | ASND | Downgrade | Neutral (Outperform) |
107.22 (136.93) |
27.71% | Details | |
| 3/10/2023 | ALX Oncology | ALXO | Maintain | Outperform (N/A) |
|
Details | ||
| 2/28/2023 | BioMarin Pharmaceutical Inc. | BMRN | Maintain | Outperform (N/A) |
|
Details | ||
| 12/16/2022 | Viridian Therapeutic | VRDN | New Coverage | Outperform (N/A) |
27.92 (12.70) |
-54.51% | Details | |
| 11/18/2022 | Editas Medicine | EDIT | Downgrade | Neutral (Outperform) |
12.25 (5.22) |
-57.39% | Details | |
| 11/8/2022 | Mariner Energy Inc. | ME | Maintain | Outperform (N/A) |
|
Details | ||
| 11/8/2022 | Apellis Pharmaceuticals | APLS | Maintain | Neutral (N/A) |
|
Details | ||
| 11/4/2022 | BioAtla Inc. | BCAB | Maintain | Neutral (N/A) |
|
Details | ||
| 11/3/2022 | Ascendis Pharma | ASND | Maintain | Outperform (N/A) |
|
Details | ||
| 10/27/2022 | BioMarin Pharmaceutical Inc. | BMRN | Maintain | Outperform (N/A) |
|
Details | ||
| 9/12/2022 | Ventyx Biosciences Inc | VTYX | Maintain | Outperform (N/A) |
|
Details | ||
| 9/6/2022 | Iveric Bio | ISEE | Maintain | Outperform (N/A) |
|
Details | ||
| 9/2/2022 | Forma Therapeutics | FMTX | Downgrade | Neutral (Outperform) |
20.24 (20.01) |
-1.14% | Details | |
| 8/16/2022 | Ventyx Biosciences Inc | VTYX | Maintain | Outperform (N/A) |
|
Details | ||
| 8/15/2022 | Pyxis Oncology Inc. | PYXS | Maintain | Outperform (N/A) |
|
Details | ||
| 8/10/2022 | BioAtla Inc. | BCAB | Maintain | Neutral (N/A) |
|
Details | ||
| 8/10/2022 | AbCellera Biologics | ABCL | Maintain | Outperform (N/A) |
|
Details | ||
| 8/9/2022 | Apellis Pharmaceuticals | APLS | Maintain | Neutral (N/A) |
|
Details | ||
| 8/9/2022 | ALX Oncology | ALXO | Maintain | Outperform (N/A) |
|
Details | ||
| 8/4/2022 | BioMarin Pharmaceutical Inc. | BMRN | Maintain | Outperform (N/A) |
|
Details | ||
| 8/3/2022 | United Therapeutics Corp. | UTHR | Maintain | Outperform (N/A) |
|
Details | ||
| 8/3/2022 | Editas Medicine | EDIT | Maintain | Outperform (N/A) |
|
Details | ||
| 7/13/2022 | Humanigen | HGEN | Downgrade | Underperform (Neutral) |
2.99 (0.04) |
-98.66% | Details | |
| 7/13/2022 | Kura Oncology | KURA | Maintain | Outperform (N/A) |
|
Details | ||
| 6/27/2022 | BioMarin Pharmaceutical Inc. | BMRN | Maintain | Outperform (N/A) |
|
Details | ||
| 5/27/2022 | Mariner Energy Inc. | ME | Maintain | Outperform (N/A) |
|
Details | ||
| 5/23/2022 | United Therapeutics Corp. | UTHR | Maintain | Outperform (N/A) |
|
Details | ||
| 5/13/2022 | Inflarx NV | IFRX | Maintain | Underperform (N/A) |
|
Details | ||
| 5/12/2022 | Ascendis Pharma | ASND | Maintain | Outperform (N/A) |
|
Details | ||
| 5/9/2022 | Ventyx Biosciences Inc | VTYX | Maintain | Outperform (N/A) |
|
Details | ||
| 5/5/2022 | Apellis Pharmaceuticals | APLS | Maintain | Neutral (N/A) |
|
Details | ||
| 5/5/2022 | BioAtla Inc. | BCAB | Downgrade | Neutral (Outperform) |
3.83 (2.25) |
-41.25% | Details | |
| 5/4/2022 | United Therapeutics Corp. | UTHR | Maintain | Outperform (N/A) |
|
Details | ||
| 5/4/2022 | Editas Medicine | EDIT | Maintain | Outperform (N/A) |
|
Details | ||
| 5/4/2022 | Iveric Bio | ISEE | Maintain | Outperform (N/A) |
|
Details | ||
| 4/19/2022 | United Therapeutics Corp. | UTHR | Maintain | Outperform (N/A) |
|
Details | ||
| 3/23/2022 | Absci Corp. | ABSI | Maintain | Outperform (N/A) |
|
Details | ||
| 3/14/2022 | Ascendis Pharma | ASND | Maintain | Outperform (N/A) |
|
Details | ||
| 3/3/2022 | argenx SE | ARGX | Maintain | Neutral (N/A) |
|
Details | ||
| 3/3/2022 | Ascendis Pharma | ASND | Maintain | Outperform (N/A) |
|
Details | ||
| 2/28/2022 | ALX Oncology | ALXO | Maintain | Outperform (N/A) |
|
Details | ||
| 2/25/2022 | AbCellera Biologics | ABCL | Maintain | Outperform (N/A) |
|
Details | ||
| 2/25/2022 | Kura Oncology | KURA | Maintain | Outperform (N/A) |
|
Details | ||
| 12/20/2021 | argenx SE | ARGX | Maintain | Neutral (N/A) |
|
Details | ||
| 11/24/2021 | Kura Oncology | KURA | Maintain | Outperform (N/A) |
|
Details | ||
| 11/11/2021 | Mariner Energy Inc. | ME | Maintain | Outperform (N/A) |
|
Details | ||
| 11/11/2021 | Ascendis Pharma | ASND | Maintain | Outperform (N/A) |
|
Details | ||
| 11/2/2021 | Pyxis Oncology Inc. | PYXS | New Coverage | Outperform (N/A) |
13.34 (4.30) |
-67.77% | Details | |
| 9/10/2021 | Apellis Pharmaceuticals | APLS | Maintain | Neutral (N/A) |
|
Details | ||
| 9/10/2021 | Iveric Bio | ISEE | Maintain | Outperform (N/A) |
|
Details | ||
| 9/9/2021 | Humanigen | HGEN | Downgrade | Neutral (Outperform) |
15.11 (2.99) |
-80.21% | Details | |
| 8/26/2021 | Ascendis Pharma | ASND | Maintain | Outperform (N/A) |
|
Details | ||
| 8/24/2021 | ALX Oncology | ALXO | Maintain | Outperform (N/A) |
|
Details | ||
| 8/17/2021 | 23andMe Holding Co. | ME | New Coverage | Outperform (N/A) |
7.60 (0.46) |
-93.95% | Details | |
| 8/16/2021 | Absci Corp. | ABSI | New Coverage | Outperform (N/A) |
23.85 (4.46) |
-81.3% | Details | |
| 8/13/2021 | Humanigen | HGEN | Maintain | Outperform (N/A) |
|
Details | ||
| 8/13/2021 | AbCellera Biologics | ABCL | Maintain | Outperform (N/A) |
|
Details | ||
| 8/10/2021 | Apellis Pharmaceuticals | APLS | Maintain | Neutral (N/A) |
|
Details | ||
| 8/2/2021 | Immunovant | IMVT | Downgrade | Underperform (Neutral) |
10.46 (27.75) |
165.3% | Details | |
| 7/6/2021 | ALX Oncology | ALXO | Maintain | Outperform (N/A) |
|
Details | ||
| 7/6/2021 | Iveric Bio | ISEE | Maintain | Outperform (N/A) |
|
Details | ||
| 6/11/2021 | Humanigen | HGEN | New Coverage | Outperform (N/A) |
21.60 (15.11) |
-30.05% | Details | |
| 6/1/2021 | Immunovant | IMVT | Maintain | Neutral (N/A) |
|
Details | ||
| 5/17/2021 | Apellis Pharmaceuticals | APLS | Maintain | Neutral (N/A) |
|
Details | ||
| 5/14/2021 | AbCellera Biologics | ABCL | Maintain | Outperform (N/A) |
|
Details | ||
| 5/13/2021 | Inflarx NV | IFRX | Maintain | Underperform (N/A) |
|
Details | ||
| 5/5/2021 | United Therapeutics Corp. | UTHR | Maintain | Outperform (N/A) |
|
Details | ||
| 5/5/2021 | Kura Oncology | KURA | New Coverage | Outperform (N/A) |
26.74 (19.00) |
-28.95% | Details | |
| 5/5/2021 | BioAtla Inc. | BCAB | New Coverage | Outperform (N/A) |
46.85 (2.25) |
-95.2% | Details | |
| 5/5/2021 | ALX Oncology | ALXO | New Coverage | Outperform (N/A) |
62.83 (16.87) |
-73.15% | Details | |
| 5/4/2021 | VectivBio Holding AG | VECT | New Coverage | Outperform (N/A) |
15.55 (16.85) |
8.36% | Details | |
| 4/29/2021 | Apellis Pharmaceuticals | APLS | Maintain | Neutral (N/A) |
|
Details | ||
| 4/12/2021 | AbCellera Biologics | ABCL | Maintain | Outperform (N/A) |
|
Details | ||
| 3/30/2021 | Forma Therapeutics | FMTX | Maintain | Outperform (N/A) |
|
Details | ||
| 3/25/2021 | BioAtla Inc. | BCAB | Maintain | Outperform (N/A) |
|
Details | ||
| 3/22/2021 | Editas Medicine | EDIT | New Coverage | Outperform (N/A) |
43.25 (5.22) |
-87.93% | Details | |
| 3/11/2021 | Ascendis Pharma | ASND | Maintain | Outperform (N/A) |
|
Details | ||
| 3/3/2021 | Iveric Bio | ISEE | Maintain | Outperform (N/A) |
|
Details | ||
| 2/17/2021 | Immunovant | IMVT | Maintain | Neutral (N/A) |
|
Details | ||
| 2/2/2021 | Immunovant | IMVT | Downgrade | Neutral (Outperform) |
43.30 (10.46) |
-75.84% | Details | |
| 2/1/2021 | argenx SE | ARGX | Maintain | Neutral (N/A) |
|
Details | ||
| 1/29/2021 | AbCellera Biologics | ABCL | Maintain | Outperform (N/A) |
|
Details | ||
| 1/29/2021 | Apellis Pharmaceuticals | APLS | Maintain | Neutral (N/A) |
|
Details | ||
| 1/5/2021 | AbCellera Biologics | ABCL | New Coverage | Outperform (N/A) |
39.10 (3.63) |
-90.72% | Details | |
| 12/8/2020 | Forma Therapeutics | FMTX | Maintain | Outperform (N/A) |
|
Details | ||
| 11/13/2020 | Immunovant | IMVT | Maintain | Outperform (N/A) |
|
Details | ||
| 11/12/2020 | Ascendis Pharma | ASND | Maintain | Outperform (N/A) |
|
Details | ||
| 11/10/2020 | Intercept Pharmaceuticals | ICPT | Maintain | Neutral (N/A) |
|
Details | ||
| 10/2/2020 | Immunovant | IMVT | New Coverage | Outperform (N/A) |
35.19 (43.30) |
23.05% | Details | |
| 8/13/2020 | Iveric Bio | ISEE | New Coverage | Outperform (N/A) |
4.40 (39.95) |
807.95% | Details | |
| 7/31/2020 | Inflarx NV | IFRX | Maintain | Underperform (N/A) |
|
Details | ||
| 7/31/2020 | Apellis Pharmaceuticals | APLS | Maintain | Neutral (N/A) |
|
Details | ||
| 7/30/2020 | argenx SE | ARGX | Maintain | Neutral (N/A) |
|
Details | ||
| 7/14/2020 | Forma Therapeutics | FMTX | New Coverage | Outperform (N/A) |
43.54 (20.01) |
-54.04% | Details | |
| 6/30/2020 | Intercept Pharmaceuticals | ICPT | Downgrade | Neutral (Outperform) |
77.49 (19.00) |
-75.48% | Details | |
| 5/21/2020 | argenx SE | ARGX | Maintain | Neutral (N/A) |
|
Details | ||
| 5/20/2020 | Ascendis Pharma | ASND | Maintain | Outperform (N/A) |
|
Details | ||
| 1/9/2020 | argenx SE | ARGX | Maintain | Neutral (N/A) |
|
Details | ||
| 1/8/2020 | Apellis Pharmaceuticals | APLS | Maintain | Neutral (N/A) |
|
Details | ||
| 1/7/2020 | Apellis Pharmaceuticals | APLS | Maintain | Neutral (N/A) |
|
Details | ||
| 12/17/2019 | Intercept Pharmaceuticals | ICPT | Maintain | Outperform (N/A) |
|
Details | ||
| 11/5/2019 | Apellis Pharmaceuticals | APLS | New Coverage | Neutral (N/A) |
30.61 (47.93) |
56.58% | Details | |
| 11/5/2019 | argenx SE | ARGX | New Coverage | Neutral (N/A) |
127.65 (368.60) |
188.76% | Details | |
| 3/29/2019 | Ascendis Pharma | ASND | Maintain | Outperform (N/A) |
|
Details | ||
| 11/29/2018 | Ascendis Pharma | ASND | Maintain | Outperform (N/A) |
|
Details | ||
| 11/9/2018 | Ascendis Pharma | ASND | New Coverage | Outperform (N/A) |
65.07 (107.22) |
64.78% | Details |
